Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Irbesartan

Irbesartan

Angiotensin receptor blocker (ARB)

AdultARBHTNCKDDiabetes

Indication

HTN β€’ diabetic kidney disease context β€’ ACEi-cough alternative

At a glance

INDICATIONS (CORE USE)

HTN and diabetic kidney disease/albuminuria pathways; ACEi alternative when cough limits use.

ADULT DOSE (STANDARD)

PO START 75–150 mg daily, titrate with BP/labs.

MAX DOSE

Common max 300 mg/day.

Route

PO once-daily profile

PEDIATRIC DOSE

Not routine.

Do not miss

Must-not-miss safety points

Major warning

- Pregnancy contraindicated β†’ DO NOT use - Monitor creatinine + potassium after start/dose changes

Indications

USE IF: HTN and diabetic CKD/albuminuria pathways. AVOID IF: pregnancy, bilateral renal artery stenosis, baseline hyperkalemia, or active hypoperfusion.

Primary

  • Hypertension
  • Diabetic kidney disease / albuminuria contexts

Secondary

  • CKD proteinuria ARB-based pathways

Dosing

STANDARD (ADULT PO)

START low/moderate and titrate with renal/electrolyte surveillance.

ADULT DOSE

Common start 75–150 mg daily; titrate to BP and kidney/lab targets.

PEDIATRIC DOSE

N/A

MAX DOSE

Common max 300 mg/day.

Practical Note

Do not escalate without recent creatinine/potassium review.

Warnings

Clinical warnings

  • Lower cough/angioedema risk vs ACE inhibitors, but not zero
  • First-dose hypotension risk (especially HF / volume depletion)
  • Renal perfusion-dependent β†’ creatinine rise possible

Contraindications

  • Pregnancy
  • Bilateral renal artery stenosis (known/suspected)
  • Baseline K+ β‰₯5.5 mmol/L

Drug interactions

  • ACE inhibitor / aliskiren combination: avoid routine dual RAAS blockade (AKI, hyperkalemia, hypotension risk)
  • Potassium-sparing agents / supplements: hyperkalemia risk
  • NSAIDs β†’ ↑ AKI risk + ↓ ARB effect β€” avoid or monitor closely
  • Potassium-sparing agents/supplements increase hyperkalemia risk.

Special populations

Pediatrics

Not routine.

Pregnancy

Pregnancy: contraindicated.

Lactation

specialist guidance.

Renal impairment

Frequent creatinine/potassium checks after initiation and titration.

Hepatic impairment

No major dose logic beyond clinical tolerance and BP response.

Elderly

Start lower and titrate cautiously.

Administration

PO daily with strict lab follow-up windows.

Monitoring

  • Recheck: - Check creatinine + potassium within 1–2 weeks after initiation - Recheck creatinine + potassium within 1–2 weeks after dose increase - Check earlier if CKD, elderly, volume depletion, or interacting drugs
  • Hold if:
    - HOLD if:
    - SBP <90–100
    - K+ β‰₯5.5 mmol/L
    - creatinine rise >30% from baseline
    - symptomatic hypotension
  • If targets not met after reassessment of dose, organ function, and interactions β†’ escalate per protocol (DO NOT continue blindly)

Overdose / toxicity

Clinical Picture

A) Mild β†’ dizziness, hypotension, fatigue B) Moderate β†’ persistent hypotension, AKI trend, hyperkalemia C) Severe β†’ refractory shock, severe hyperkalemia, respiratory compromise

Immediate Actions

β€’ Airway + continuous monitoring (ABC, BP, telemetry) β€’ Hypotension β†’ IV fluids first-line β€’ Refractory hypotension β†’ early vasopressors β€’ Stop ARB immediately

Antidote

- No specific antidote - Supportive care + hemodynamic stabilization - Hyperkalemia treatment β†’ calcium + insulin/dextrose + potassium-shifting protocol

Decontamination

β€’ Recent oral ingestion β†’ activated charcoal if protected airway and early presentation (toxicology-guided)

Escalation

- Refractory hypotension β†’ ICU / vasopressors - Severe hyperkalemia / AKI β†’ nephrology + renal replacement planning if indicated

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

Irbesartan identity: strong HTN + diabetic kidney disease orientation.

Clinical pearls

Do not overlook early potassium drift in diabetic CKD pathways.

ARB safety

    Pharmacokinetics

    Once-daily use common with durable BP control in many adults.

    Mechanism of action

    Selective AT1 receptor blockade reduces RAAS downstream effects.

    Common brand names

    Saudi Arabia

    Aprovel, Avapro

    Global

    (placeholder β€” verify local formulation)

    Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

    Country practice notes

    Global data (no country-specific data available)

    • Follow local antimicrobial stewardship policy, hospital formulary, and national resistance guidance.
    • Confirm dosing, stock, and restrictions with institutional pharmacy and current product labeling.

    References

    Saudi Arabia

    • SFDA (Saudi Food & Drug Authority)
    • Saudi National Formulary / MOH (where available)

    International

    • WHO Model List of Essential Medicines (verify current edition)
    • US FDA or EU EMA product information (when national SmPC is unavailable)
    • ACC / AHA HF, HTN, CKD guidance
    • KDIGO CKD / albuminuria guidance
    • FDA / SFDA product labeling

    Do not miss

    • Pregnancy contraindicated β†’ DO NOT use
    • Hyperkalemia risk β†’ monitor potassium early
    • Creatinine rise / AKI risk (bilateral renal artery stenosis / volume depletion)
    • First-dose hypotension β†’ correct volume before starting